Drugs that contain Lisdexamfetamine Dimesylate

1. Drug name - VYVANSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(4 months from now)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(4 months from now)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(4 months from now)

CN1747737A TAKEDA PHARMS USA Saccharide Conjugates Prevent Abuse Of The Control Medicine
Sep, 2011

(11 years ago)

CN101193650A TAKEDA PHARMS USA Abuse-Resistance Amphetamine Prodrugs
Dec, 2012

(9 years ago)

CN1476325A TAKEDA PHARMS USA Conveying System And Method Of Protecting And Administering Active Material Active Material
Oct, 2015

(6 years ago)

CN1476325B TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Oct, 2015

(6 years ago)

CN100413533C TAKEDA PHARMS USA A Pharmaceutical Compound For Preventing Sustained Release Of Control Of Substance Abuse
Feb, 2022

(7 months ago)

CN1720059A TAKEDA PHARMS USA Sustained Release Model Of Preventing Substance Abuse Of A Pharmaceutical Compound
Feb, 2022

(7 months ago)

CN1816346A TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

CN1816346B TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

CN1925865B TAKEDA PHARMS USA Pharmaceutical Composition Of Preventing Overdose Or Abuse
Sep, 2024

(1 year, 11 months from now)

CN1925865A TAKEDA PHARMS USA Pharmaceutical Compositions For Prevention Of Overdose Or Abuse
Sep, 2024

(1 year, 11 months from now)

IN200401300P2 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

IN231459B TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

IN250464B TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

IN200502683P2 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds Cross Reference Related Applications
Jun, 2024

(1 year, 7 months from now)

EP1311242A4 TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Aug, 2021

(1 year, 1 month ago)

EP1311242B1 TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Aug, 2021

(1 year, 1 month ago)

EP1311242A1 TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Aug, 2021

(1 year, 1 month ago)

EP1401374A1 TAKEDA PHARMS USA A Novel Pharmaceutical Compound Containing Atenolol And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1401374B1 TAKEDA PHARMS USA A Novel Pharmaceutical Compound Containing Atenolol And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1401374A4 TAKEDA PHARMS USA A Novel Pharmaceutical Compound Containing Abacavir Sulfate And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1357928A2 TAKEDA PHARMS USA A Novel Pharmaceutical Compound And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1357928B1 TAKEDA PHARMS USA A Novel Pharmaceutical Compound And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1357928A4 TAKEDA PHARMS USA A Novel Pharmaceutical Compound And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1531844A4 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

EP1531844A2 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

EP1531844B1 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

EP1594513B1 TAKEDA PHARMS USA Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances
Jan, 2024

(1 year, 3 months from now)

EP1594513A4 TAKEDA PHARMS USA Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances
Jan, 2024

(1 year, 3 months from now)

EP1594513A2 TAKEDA PHARMS USA Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances
Jan, 2024

(1 year, 3 months from now)

EP1644019A1 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

EP1644019A4 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

EP1644019B1 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

EP1644019B2 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds Feb, 2023

(4 months from now)

US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds Feb, 2023

(4 months from now)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds Aug, 2023

(10 months from now)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds Aug, 2023

(10 months from now)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds Aug, 2023

(10 months from now)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

Treatment: Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, CHEWABLE;ORAL Prescription
20MG TABLET, CHEWABLE;ORAL Prescription
30MG TABLET, CHEWABLE;ORAL Prescription
40MG TABLET, CHEWABLE;ORAL Prescription
50MG TABLET, CHEWABLE;ORAL Prescription
60MG TABLET, CHEWABLE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.